Drug development

Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.

Hiring and Beyond: How to Resource Data Scientists in your Business

In any field, data science is an emerging area where roles can be hard to define or quantify by hiring managers. For those looking to employ data scientists within their business, this role can lead to a wealth of unanswered questions. This chapter from our Data Solutions for Drug Development Report, sets out key tips […]

First AI-Designed Vaccine Created

Researchers have revealed the first vaccine purely designed by artificial intelligence (AI). This has the potential to revolutionise the drug discovery process by making it quicker, cheaper and producing more effective drugs. From target discovery to market, the drug discovery process takes on average nine years and millions of dollars. The majority of this time […]

Data Solutions for Drug Development Report

The pharmaceutical industry is capturing an ever-increasing quantity of data, but this is often underutilised by professionals in the perfect place to use this data to their advantage. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or miss […]

Abbvie Acquires Allergan for $63 Billion

Biopharma giant Abbvie has announced the acquisition of Allergan for $63 billion in cash and stock. Abbvie said the deal would be “transformational” for both companies, allowing Abbvie to diversify its business while focusing on scientific research and the company’s pipeline.

Real-World Solutions to your Drug Development Problems

The amount of data captured by pharma companies today is fast outpacing best use for it. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or missing a potential opportunity that their rivals seize. Stemming from Front Line Genomics’ […]

New Approaches to the Old Hunt for NASH Therapies

Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH is characterized by […]

Takeda Divests Drugs to Novartis and Ethicon for $5.3 Billion

Takeda Pharmaceutical has announced the sizeable first sale in its proposed £10 billion-worth of assets to offset the debt it took on during its acquisition of Shire. The company announced it was divesting eye drug Xiidra to Novartis for $5.3bn total, and its TachoSil Fibrin Sealant Patch to Ethicon for $400 million in case.

Patients with Rare Diseases Identified Through Genomics England’s Discovery Forum

Two companies with access to data from the 100,000 Genomes Project have identified patients with previously undiscovered life-threatening kidney and neurological diseases. The companies, Alexion and BioMarin, were part of Genomic England’s Discovery Forum, which grants certain industry research proposals access to data from the project after vetting.

Two Studies Find Reasons for IO Drug Resistance

Two separate studies have uncovered insights into why checkpoint-inhibiting immune-oncology (IO) drugs only work for a minority of patients, even when combined with other treatments. The first study uncovered a resistance mechanism within the gut microbiome, while the other relates to cancer cell-produced vesicles.

nQ Medical Wins “Most Innovative Breakthrough” Prize at D4 Conference

Out of a whole host of engaging and enjoyable moments at Front Line Genomics’ recent Data Driven Drug Development (D4) conference, held in Boston on 20-21 March, one of the most memorable was definitely the triumph of nQ Medical in our innovation showcase, beating out three other contenders for the claim to be “most innovative” of the technologies on display.